<DOC>
	<DOCNO>NCT01323465</DOCNO>
	<brief_summary>Study assess effect rifampicin , ketoconazole omeprazole pharmacokinetics single dose Sativex evaluate safety Sativex give combination drug .</brief_summary>
	<brief_title>Study Evaluate Effect Rifampicin , Ketoconazole , Omeprazole Pharmacokinetics Sativex</brief_title>
	<detailed_description>An open-label , randomise , crossover , drug interaction study . Subjects divide three group within group , subject randomise one two treatment sequence . Subjects receive 4 spray Sativex alongside either dos rifampicin , ketoconazole omeprazole .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Healthy male subject 18 45 year age ( inclusive ) . Subjects body mass index 1830 kg/m2 ( inclusive ) calculate : Weight ( kg ) /height ( m2 ) . No clinically significant abnormal finding physical examination , ECG , medical history , clinical laboratory result screen . Subjects , opinion investigator , clinically significant abnormal finding renal hepatic function determine serum creatinine , total bilirubin , transaminase level . Subjects nonusers tobacco product ( minimum 6 month prior start study ) . Subjects negative screen HIV I II , HBsAg . antibody hepatitis C. Subjects negative urine screen alcohol , drug abuse ( screen ) , cotinine . Subjects use appropriate barrier method contraception ( condom spermicide ) addition female partner use another form barrier contraception ( e.g . female condom occlusive cap [ diaphragm cervical vault/caps ] spermicide ) study 3 month follow administration study drug . Subjects able comply protocol restriction assessment therein . Subjects give voluntary write informed consent participate trial . Subjects history presence significant cardiovascular , pulmonary , hepatic , renal , haematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . Subjects history presence family history schizophrenia , psychotic illness , severe personality disorder , depression , significant psychiatric disorder . Subjects postural drop 20 mmHG systolic blood pressure screen . Subjects participate previous clinical trial within 90 day prior study initiation . Subjects donate plasma within 90 day prior study initiation . Subjects donate blood within 90 day prior study initiation . Subjects abnormal diet substantial change eat habit within 30 day prior study initiation . Subjects treatment know enzymealtering agent ( barbiturate , phenothiazine , cimetidine etc . ) within 30 day prior study . Subjects history know hypersensitivity idiosyncratic reaction study drug related compound . Subjects use prescription medication within 14 day prior study . Subjects use overthecounter medication within 7 day prior study . Subjects history alcohol drug abuse within 2 year prior study ( subject history previous use cannabis exclude unless use cannabis cannabinoid base medicine within 30 day prior study drug administration unwilling abstain duration study ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sativex</keyword>
	<keyword>Cytochrome P450</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Cannabinoids</keyword>
	<keyword>ketoconazole</keyword>
	<keyword>omeprazole</keyword>
	<keyword>rifampicin</keyword>
</DOC>